Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 3, 2018
Reporting Period: Quarter and six months ended June 30, 2018
Status: Emerging Growth Company (elected not to use extended transition period for new accounting standards)
Key Financial Metrics
This Form 8-K serves as a notification of the issuance of a press release regarding financial results. The filing text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained in the referenced press release (Exhibit 99.1) and are not explicitly stated in the body of this document.
Material Changes
The filing does not provide specific comparative data or material changes versus prior periods. It solely references the announcement of results for the period ended June 30, 2018.
Guidance, Outlook, and Risks
Management Commentary: The company announced a conference call to discuss financial results and business updates.
Legal Disclaimer: In accordance with General Instruction B.2 of Form 8-K, the information in Item 2.02 and the attached press release is not deemed "filed" under Section 18 of the Exchange Act and is not subject to the liability of that section. It is not incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 3, 2018) for specific revenue, net loss, and cash position figures.
- Verify the details of the conference call mentioned for business updates and guidance.
- Confirm the company's status as an Emerging Growth Company and its election regarding accounting standard transition periods.
- Note that the financial data in the press release is not legally "filed" for liability purposes under Section 18 of the Exchange Act.